HER2 Antibody Clone: GR011 Concentrate
- Known as:
- HER2 Antibody Clone: GR011 Concentrate
- Catalog number:
- 61-0154-2
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- HER2 Antibody Clone: GR011 Concentrate
Related genes to: HER2 Antibody Clone: GR011 Concentrate
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 Antibody Clone: GR011 Concentrate
Related articles to: HER2 Antibody Clone: GR011 Concentrate
- Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype associated with a poor prognosis when not optimally treated. Over the past year, major advances-including results from DESTINY-Breast05, DESTINY-Breast09, DESTINY-Breast11, PATINA, and long-term APHINITY follow-up-have changed the treatment landscape regarding the place in therapy of antibody-drug conjugates and the optimal sequencing of systemic therapies. These developments prompted the need for updated evidence-informed consensus recommendations to support consistent, high-quality care across Canada. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), comprising clinical-academic oncologists from across Canada and Breast Cancer Canada, updated its 2024 HER2+ recommendations through a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% agreement. This 2025 update incorporates new data in early-stage, metastatic, and central nervous system-involved disease, including revisions to neoadjuvant and adjuvant treatment pathways and expanded guidance on the clinical use of antibody-drug conjugates. - Source: PubMed
Publication date: 2026/03/31
Kumar AalokJerzak Katarzyna JGelmon Karen ABoileau Jean-FrançoisBouganim NathanielBrezden-Masley ChristineCao Jeffrey QCescon David WChia StephenEdwards ScottJoy Anil AbrahamLaing KaraLeVasseur NathalieSehdev SandeepSimmons ChristineWebster MarcManna MitaOn Behalf Of Patient Advocacy Breast Cancer Canada - Most patients with advanced/metastatic hormone receptor-positive, HER2-negative breast cancer receive first-line therapy with cycline-dependent kinase 4/6 inhibitors plus endocrine therapy. Almost universally, these patients eventually progress due to the emergence of resistant cancer clones. Targeting the PIK3CA/AKT1/PTEN pathway is a way of overcoming resistance. Recently, the oral, selective AKT kinase inhibitor capivasertib has been approved for the treatment of estrogen receptor-positive/human HER2-growth factor receptor-2 advanced BC with alterations in PIK3CA/AKT1/PTEN, in combination with fulvestrant after progression on endocrine therapy. We performed a narrative review to recapitulate the available evidence about capivasertib in the management of advanced hormone receptor-positive, HER2-negative breast cancer, focusing on studies that address preclinical rationale, pharmacology, and clinically relevant problems. - Source: PubMed
Publication date: 2026/03/31
Valerio Maria RosariaSambataro DanielaMartorana FedericaGreco MartinaMesi ChiaraGebbia VittorioVigneri PaoloScandurra Giuseppa - Limited data exist on the prevalence of human epidermal growth factor receptor 2 (/) amplification in patients with all types of solid tumors. This retrospective, observational study (UMIN ID: UMIN000057382) analyzed the prevalence of amplification across all solid tumors using comprehensive genomic profiling (CGP) data from the Center for Cancer Genomics and Advanced Therapeutics database in Japan. We analyzed 89,374 eligible patients with solid tumors: amplification was detected in 5119 patients (5.7%). The highest rates of amplification were observed in patients with tumors of the esophagus/stomach (12.9%), followed by tumors of the bladder/urinary tract (10.6%), breast (9.5%), biliary tract (8.4%), and uterus (8.4%). Among the five assay platforms, FoundationOne CDx accounted for 69.7% of all CGP tests and had an amplification detection rate of 7.4%, compared to the other four platforms (range: 1.9-15.4% of all CGP tests [detection rates: 1.5-2.3%]). Substantial differences were observed in the mutation frequencies of multiple genes between amplified and non-amplified tumors. The results highlight that amplification extends beyond conventional tumor types and enables the identification, via CGP testing, of non-traditional tumor subsets (cancers other than breast and gastric cancer), including rare cancers, that could be candidates for -targeting therapy such as trastuzumab deruxtecan in Japan. - Source: PubMed
Publication date: 2026/03/30
Hatanaka YutakaSasano JunTakizawa Osamu - In September 2022, the US Food and Drug Administration (FDA) expanded approval of the legacy Roche monoclonal antibody 4B5-based immunohistochemistry (IHC) assay to identify patients with HER2-low breast cancers predicted to respond to trastuzumab deruxtecan (T-DXd), based on findings from the DESTINY-Breast04 and DESTINY-Breast06 clinical trials. However, this repurposing of a legacy biomarker assay raises significant clinical and technical validation concerns. The legacy HER2 IHC assay was originally developed to identify tumors with HER2 overexpression (3+) resulting from gene amplification, which leads to substantially higher HER2 receptor expression than in low/ultralow expression tumors. The current application to distinguish HER2-low and HER2-ultralow tumors from truly HER2-negative tumors represents a fundamentally different biological and clinical purpose, yet the assay's analytical and clinical validation for this new purpose remains incomplete. Critical gaps include the lack of established analytical sensitivity and specificity for identifying 1+ HER2 cases, poor reproducibility of pathologist scoring at low HER2 levels, and the absence of alternative methodologies for orthogonal validation. While more sensitive quantitative approaches (such as AQUA) may detect additional low HER2 expression cases missed by conventional IHC, increased analytical sensitivity does not automatically translate to clinical utility. Furthermore, the ASCO/CAP guidelines cutoffs were developed for HER2 overexpression detection and may not be the best choice for HER2-low/ultralow identification without clinical validation and determination of fit-for-purpose analytical specifications. We examine the current challenges of repurposing legacy HER2 IHC biomarker assays for HER2-low detection, evaluating the precedent of other repurposed IHC assays (ALK, CD30, and PD-L1), and emphasizing the necessity for proper technical and clinical validation before widespread implementation. We conclude that prospective clinical trials are essential to establish clinically meaningful cutoffs and analytical specifications appropriate for patient selection in HER2-low disease. - Source: PubMed
Publication date: 2026/03/25
Torlakovic Emina EGown Allen M - Accurate intrinsic molecular subtyping is essential for precision management of breast cancer, yet multi-omics integration remains challenging due to high dimensionality, structured cross-omics dependencies, and the need for clinically interpretable and reliable predictions. - Source: PubMed
Publication date: 2026/04/10
Li ChenZhang ZhenZhang Chun